Synthetic composition and method for treating irritable bowel syndrome

Abstract

The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for use treating irritable bowel syndrome.

1 . A synthetic composition for use
 in treating a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in reducing an irritable bowel syndrome (IBS) symptom in a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in treating one or more chronic symptoms of abdominal pain, abdominal discomfort and/or abdominal bloating of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in treating one or more chronic symptoms of changes in bowel movement patterns, such as patterns of loose or more frequent bowel movements, diarrhoea and constipation, of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in preventing re-occurrence of IBS in a former patient with IBS, particularly a former patient who previously had one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   increasing Bifidobacteria, preferably Bifidobacterium adolescentis, in the colon of an IBS patient for reducing IBS symptoms in the patient, particularly a patient having one or more of bacterial overgrowth, and/or dysbiosis and an impaired mucosal barrier, and/or   in preventing IBS or IBS symptoms in a patient who is undergoing or who has undergone treatment with an antibiotic, characterised in that the composition contains an effective amount of a human milk monosaccharide (HMS) or a human milk oligosaccharide (HMO), or both.   
     
     
         2 . The composition according to  claim 1  which is a nutritional composition. 
     
     
         3 . The composition according to  claim 1 , wherein the HMS is selected from sialic acid and fucose, and the HMO is selected from 2′-FL, 3-FL, DFL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I and DSLNT. 
     
     
         4 . The composition according to  claim 1  containing one or more backbone HMOs, one or more sialyl HMOs and one or more fucosyl HMOs, and optionally fucose and/or sialic acid, preferably both. 
     
     
         5 . The composition according to  claim 4  containing 2′-FL and LNnT. 
     
     
         6 . A method for
 treating a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   reducing an IBS symptom in an IBS patient, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   treating one or more IBS symptoms of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   treating one or more chronic symptoms of changes in bowel movement patterns, such as patterns of loose or more frequent bowel movements, diarrhoea and constipation, of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   preventing re-occurrence of IBS in a former patient with IBS, particularly a former patient who previously had one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   increasing Bifidobacteria, preferably Bifidobacterium adolescentis, in the colon of an IBS patient for reducing IBS symptoms in the patient, particularly a patient having one or more of bacterial overgrowth, and/or dysbiosis and an impaired mucosal barrier, and/or   preventing IBS or IBS symptoms in a patient who is undergoing or who has undergone treatment with an antibiotic,   
       the method comprising orally administering to the patient an effective amount of one or more HMSs or one or more HMOs, or both, in the form of a synthetic composition. 
     
     
         7 . The method according to  claim 6 , wherein the synthetic composition is a nutritional composition. 
     
     
         8 . The method according to  claim 6 , wherein the HMS is selected from sialic acid and fucose, and the HMO is selected from 2′-FL, 3-FL, DFL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I and DSLNT. 
     
     
         9 . The method according to  claim 6 , wherein the synthetic composition contains one or more backbone HMOs, one or more sialyl HMOs and one or more fucosyl HMOs, and optionally fucose and/or sialic acid, preferably both. 
     
     
         10 . The method according to  claim 9  wherein the synthetic composition contains 2′-FL and LNnT. 
     
     
         11 . The method according to  claim 6  for improving visceral sensitivity and defecation abnormalities. 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . A human milk monosaccharide (HMS), a human milk oligosaccharide (HMO), or a mixture thereof for use
 in treating a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in reducing an irritable bowel syndrome (IBS) symptom in a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in treating one or more chronic symptoms of abdominal pain, abdominal discomfort and/or abdominal bloating of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in treating one or more chronic symptoms of changes in bowel movement patterns, such as patterns of loose or more frequent bowel movements, diarrhoea and constipation, of a patient with IBS, particularly a patient having one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   in preventing re-occurrence of IBS in a former patient with IBS, particularly a former patient who previously had one or more of bacterial overgrowth, dysbiosis and an impaired mucosal barrier,   increasing Bifidobacteria, preferably Bifidobacterium adolescentis, in the colon of an IBS patient for reducing IBS symptoms in the patient, particularly a patient having one or more of bacterial overgrowth, and/or dysbiosis and an impaired mucosal barrier, and/or   in preventing IBS or IBS symptoms in a patient who is undergoing or who has undergone treatment with an antibiotic.   
     
     
         18 . An HMS, an HMO, or a mixture thereof according to  claim 17 , wherein the HMS is selected from sialic acid and fucose, and the HMO is selected from 2′-FL, 3-FL, DFL, 3′-SL, 6′-SL, LNT, LNnT, LNFP-I and DSLNT. 
     
     
         19 . A mixture according to  claim 17  comprising one or more backbone HMOs, one or more sialyl HMOs and one or more fucosyl HMOs, and optionally fucose and/or sialic acid. 
     
     
         20 . A mixture according to  claim 19  comprising 2′-FL and LNnT.